• Briacell entered a manufacturing arrangement with FUJIFILM Biotechnologies California to support production of its Bria-IMT cell therapy.
• Deal secures capacity for the remainder of the pivotal Phase 3 metastatic breast cancer study, supporting Bria-IMT with an immune checkpoint inhibitor.
• Agreement also provides a path to scale manufacturing for potential commercial supply.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief on July 15, 2026, and is solely responsible for the information contained therein.